Nonmelanoma skin cancers are the most common malignancies in transplant recipients under immunosuppression; nevertheless, appendage tumors also may appear. The onset of several cutaneous neoplasms in transplant patients can cause deterioration in quality of life of these patients. A 62-year-old white woman patient developed several malignant and benign sebaceous neoplasms during an immunosuppressive treatment for a renal transplant. The genetic study showed a mutation in MSH6-eson 1 (c116G>A), without mutations in MLH1 gene and MSH2. A final diagnosis of multiple sebaceous tumors in an immunosuppressed patient without Muir -Torre syndrome was made. The spreading of further cutaneous neoplasms led to a change in immunosuppression: namely, that clinicians suspended tacrolimus and add everolimus. After 2 months, all tumor lesions on the face and on the limbs have disappeared, and no further lesions occurred. Everolimus could represent a valid therapeutical treatment for transplant patients at high risk for cutaneous tumors. A genetic consult and a consequent study of the genetic profile should be performed on each of these patients, to avoid risks of recurrent cutaneous tumors and negative effects on the quality of life.

Resolution of benign and malignant sebaceous neoplasms, in a renal transplant patient treated with everolimus / Donati, Michele; Paolino, Giovanni; Muscardin, Luca; Panetta, Chiara; Donati, Pietro. - In: EXPERIMENTAL AND CLINICAL TRANSPLANTATION. - ISSN 1304-0855. - 15:1(2017), pp. 100-102. [10.6002/ect.2014.0208]

Resolution of benign and malignant sebaceous neoplasms, in a renal transplant patient treated with everolimus

Paolino, Giovanni
Writing – Review & Editing
;
2017

Abstract

Nonmelanoma skin cancers are the most common malignancies in transplant recipients under immunosuppression; nevertheless, appendage tumors also may appear. The onset of several cutaneous neoplasms in transplant patients can cause deterioration in quality of life of these patients. A 62-year-old white woman patient developed several malignant and benign sebaceous neoplasms during an immunosuppressive treatment for a renal transplant. The genetic study showed a mutation in MSH6-eson 1 (c116G>A), without mutations in MLH1 gene and MSH2. A final diagnosis of multiple sebaceous tumors in an immunosuppressed patient without Muir -Torre syndrome was made. The spreading of further cutaneous neoplasms led to a change in immunosuppression: namely, that clinicians suspended tacrolimus and add everolimus. After 2 months, all tumor lesions on the face and on the limbs have disappeared, and no further lesions occurred. Everolimus could represent a valid therapeutical treatment for transplant patients at high risk for cutaneous tumors. A genetic consult and a consequent study of the genetic profile should be performed on each of these patients, to avoid risks of recurrent cutaneous tumors and negative effects on the quality of life.
2017
Cutaneous tumors; Immunosuppressive therapies; Muir-Torre syndrome; biopsy; drug substitution; everolimus; female; humans; immunocompromised ost; immunosuppressive agents; kidney transplantation; middle aged; sebaceous gland neoplasms; tacrolimus; time factors; treatment outcome; transplantation
01 Pubblicazione su rivista::01i Case report
Resolution of benign and malignant sebaceous neoplasms, in a renal transplant patient treated with everolimus / Donati, Michele; Paolino, Giovanni; Muscardin, Luca; Panetta, Chiara; Donati, Pietro. - In: EXPERIMENTAL AND CLINICAL TRANSPLANTATION. - ISSN 1304-0855. - 15:1(2017), pp. 100-102. [10.6002/ect.2014.0208]
File allegati a questo prodotto
File Dimensione Formato  
Paolino_Sebaceous-neoplasms.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 285.28 kB
Formato Adobe PDF
285.28 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1074077
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact